CYP4F30P: A Drug Target / Disease Biomarker (G100132708)

Target Name: CYP4F30P

NCBI ID: G100132708

CYP4F30P

Other Name(s): C2orf14 | cytochrome P450 family 4 subfamily F member 30, pseudogene | Cytochrome P450 family 4 subfamily F member 30, pseudogene

CYP4F30P: A Drug Target / Disease Biomarker

CYP4F30P is a gene that encodes for a protein known as CYP4F30, which is a key regulator of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the blood and protects it from harmful substances, but it also allows certain substances to enter the brain. CYP4F30P plays a crucial role in maintaining the integrity of the blood-brain barrier and is often used as a drug target or biomarker for various neurological and psychiatric disorders.

The CYP4F30 gene is located on chromosome 16 and encodes for a protein of the same name that spans 1,212 amino acids. The protein produced by the CYP4F30 gene is composed of four distinct domains: an N-terminus, a catalytic domain, a transmembrane domain, and a C-terminus. The N-terminus of CYP4F30P is a 24 amino acid residue that includes a putative N-endopeptide insertion. The catalytic domain is the most abundant and consists of 325 amino acids. It includes a Glu-215 and a Lys-216 amino acid residue, which are known as the Glu-215-Lys-216 loop. The transmembrane domain is 25 amino acids long and is responsible for the protein's ability to interact with the blood-brain barrier. The C-terminus is a 95 amino acid residue that includes a glycine-rich loop and a Glu-218 amino acid residue.

CYP4F30P is a key regulator of the blood-brain barrier and is involved in the regulation of numerous physiological processes that are critical for brain function. One of the most significant functions of CYP4F30P is its role in the regulation of neurotransmitter release from the postsynaptic terminal. The blood-brain barrier is responsible for selectively allowing certain neurotransmitters to reach the brain and modulating their levels. CYP4F30P is involved in the regulation of the release of neurotransmitters such as dopamine, serotonin, and endocannabinoids.

CYP4F30P is also involved in the regulation of neuroimmune interactions. The blood-brain barrier is the barrier between the immune system and the brain and is critical for protecting the brain from harmful pathogens and autoimmune disorders. CYP4F30P plays a role in the regulation of the movement of immune cells through the blood-brain barrier and in the regulation of the production of immune cell-derived neurotoxins.

CYP4F30P is also involved in the regulation of neuroendocrine processes. The brain produces and releases a variety of neuroendocrins that regulate various physiological processes, including stress response, appetite, and sleep. CYP4F30P is involved in the regulation of neuroendocrine processes and is thought to play a role in the regulation of the production and release of neuroendocrins.

CYP4F30P is also involved in the regulation of inflammation. The blood-brain barrier is a site of chronic inflammation and CYP4F30P is involved in the regulation of the inflammatory response. It is thought to play a role in the regulation of the production and release of pro-inflammatory cytokines and in the regulation of the recruitment of immune cells to the site of inflammation.

CYP4F30P is a potential drug target or biomarker for a variety of neurological and psychiatric disorders. The disruption of

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 30, Pseudogene

The "CYP4F30P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F30P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets